NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ABBOTINDIA · data 2026-10-31
Abbott India Limited
In plain words
Price: 16.4% below its 52-week high of ₹30,655.
Delivery: 54.0% of traded shares were kept for delivery over the last 10 sessions, against 54.7% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹7,004 cr |
| Net profit (last 12 months) | ₹1,615 cr |
| Sales growth, 3 years (yearly) | 9.0% |
| Profit growth, 3 years (yearly) | 17.8% |
At a glance
P/E 33.7, dividend yield 2.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 34.5%, ROCE 39.1%, operating margin 27.5%: how much profit it earns on the money it uses.
Debt/equity 0.04, Profit growth 17.8% and sales growth 9.0% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (34.5%).
- Healthy operating margin (27.5%).
- Profit grew 17.8% a year over 3 years.
- Pays a dividend yielding 2.0%.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
16/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 55.9% over the last 20 sessions vs 56.0% in the 40 before (1x); shares delivered per day 0.59x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 11/15: 15 schemes hold it, about ₹1,736 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: Verdict "None", sustained score 15/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend
- 24 Jul 26Dividend Dividend ₹525 (ex-date) -3.1% next session
- 25 Jul 25Dividend Dividend ₹475 (ex-date) -4.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Common questions
Is Abbott India Limited debt-free?
Its latest reported debt-to-equity ratio is 0.04, which is very low.
What is Abbott India Limited's P/E ratio?
About 33.7, based on the last 12 months' earnings and a price of ₹25,635 (data 2026-10-31).
What is the 52-week high and low of Abbott India Limited?
The 52-week high is ₹30,655 and the 52-week low is ₹24,650.
Mutual funds holding Abbott India Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 15 schemes holding about ₹1,736 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Large and Midcap Fund | SBI Mutual Fund | 2.06% | ₹834 cr |
| Nippon India Multi Cap Fund | Nippon India Mutual Fund | 0.74% | ₹398 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 2.32% | ₹213 cr |
| ADITYA BIRLA SUN LIFE BALANCED ADVANTAGE FUND | Aditya Birla Sun Life Mutual Fund | 0.74% | ₹73 cr |
| Nippon India Vision Large & Mid Cap Fund | Nippon India Mutual Fund | 0.97% | ₹72 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 3.26% | ₹35 cr |
| ADITYA BIRLA SUN LIFE MNC FUND | Aditya Birla Sun Life Mutual Fund | 1.03% | ₹31 cr |
| NIPPON INDIA RETIREMENT FUND - WEALTH CREATION SCHEME | Nippon India Mutual Fund | 0.89% | ₹26 cr |
| Nippon India Nifty Pharma ETF | Nippon India Mutual Fund | 1.43% | ₹25 cr |
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 0.23% | ₹14 cr |
| SBI MNC Fund | SBI Mutual Fund | 0.21% | ₹13 cr |
| ADITYA BIRLA SUN LIFE NIFTY HEALTHCARE ETF | Aditya Birla Sun Life Mutual Fund | 1.22% | ₹1 cr |
| Nippon India Nifty 500 Equal Weight Index Fund | Nippon India Mutual Fund | 0.21% | ₹1 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 1.04% | ₹0 cr |
| Mirae Asset BSE 200 Equal Weight ETF | Mirae Asset Mutual Fund | 0.56% | ₹0 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Abbott India Limited | ₹25,635 | ₹54,384 cr | 33.7 | — | 34.5% | 39.1% | 0.04 | -14.2% |
| Glenmark Pharmaceuticals Limited | ₹2,298.7 | ₹65,137 cr | 36.1 | — | 14.1% | 29.2% | 0.06 | +24.1% |
| Alkem Laboratories Ltd. | ₹5,113.5 | ₹61,277 cr | 28.4 | — | 17.8% | 17.8% | 0.15 | -7.7% |
| Biocon Limited | ₹351.8 | ₹57,310 cr | 104.6 | 1.6 | 1.4% | 3.5% | 0.45 | -7.4% |
| Gland Pharma Ltd. | ₹3,095.9 | ₹51,112 cr | 45.2 | — | 10.5% | 12% | 0.03 | +62.6% |
| IPCA Laboratories Limited | ₹1,927.8 | ₹48,898 cr | 37.3 | — | 15.2% | 16.3% | 0.1 | +49.5% |
Compare ABBOTINDIA with GLENMARK in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ABBOTINDIA in NSE Scanner →